

#27  
9/03/03

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450, ON THE DATE INDICATED BELOW.

BY:

Date:

August 25, 2003

Mail Stop RCE



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In Re Patent Application of :  
Elke Bucha *et al.* :  
Conf. No.: 7560 : Group Art Unit: 1641  
Appln. No.: 09/417,534 : Examiner: G. Gabel  
Filing Date: October 14, 1999 : Attorney Docket No.: 9282-6  
Title: INTERACTIVE SYSTEM FOR PRESENTING AND ELIMINATING  
SUBSTANCES

RECEIVED  
TECH CENTER 1600/2000  
AUG 23 2003

**SUPPLEMENTARY REQUEST FOR RECONSIDERATION**

This Supplementary Request for Reconsideration is filed in response to the Advisory Action mailed August 13, 2003 in the above-identified patent application. The Supplementary Amendment is supplemental to the Amendment After Final filed June 20, 2003 and addresses a point raised in the Advisory Action. This Supplemental Amendment is accompanied by a Request for Continued Examination (RCE), which is timely filed on August 25, 2003, in view of the Petition for a two month extension of time, extending the time for response to the Final Office Action (Paper No. 22) up to and including August 25, 2003 (as August 24, 2003, was a Sunday).

## REMARKS

Claims 35-38, 42-47, and 50-55 remain pending in the application. This Supplementary Amendment After Final is submitted with an RCE, in which the applicants request entrance of the Amendment After Final, filed June 20, 2003. This Supplementary Amendment serves only to address the Examiner's comments in the Advisory Action, and is intended to be supplementary to the Amendment After Final filed June 20, 2003.

In the Advisory Action, the Examiner states that the "recitation of "polyoxaziline" in claim 35 raises an issue of new matter. As stated in the Amendment After Final filed June 20, 2003, no new matter is added by this Amendment. Linkers for use in this invention that are polyoxaziline are disclosed at least in the Specification at page 6, line 4. ("The linker can have any desired chain length. Preferably, the linker is a (poly) alkaline glycol, more preferably polyethylene glycol. Furthermore, a (poly) alkaline imine, a (poly) alkaline amine, a (poly) alkaline sulfide or a polyoxaziline is preferred.")

Application No. 09/417,554  
Reply to Advisory Action of 08/13/03

## CONCLUSION

In view of the foregoing, and the arguments and amendments set forth in the Amendment After Final filed June 20, 2003, it is respectfully submitted that the claims are in a condition for allowance. Consideration and allowance of pending claims 35-38, 42-47, and 50-55 are respectfully requested.

Respectfully submitted,

**ELKE BUCHA, et al.**

25 August 2003  
(Date)

By:

Kristyne A. Bullock

KRISTYNE A. BULLOCK

Registration No. 42,371

AKIN GUMP STRAUSS HAUER & FELD LLP

One Commerce Square

2005 Market Street, Suite 2200

Philadelphia, PA 19103-7013

Telephone: 215-965-1200

**Direct Dial: 215-965-1348**

Facsimile: 215-965-1210

E-Mail: [kbullock@akingump.com](mailto:kbullock@akingump.com)

KAB:cmb  
245499

Enclosures [Petition for Two Month Extension of Time & Request for Continued Examination]